William Blair Investment Management LLC Invests $121.39 Million in Glaukos Co. (NYSE:GKOS)

William Blair Investment Management LLC purchased a new position in Glaukos Co. (NYSE:GKOS) in the 4th quarter, HoldingsChannel reports. The fund purchased 809,589 shares of the medical instruments supplier’s stock, valued at approximately $121,390,000.

Several other large investors have also recently modified their holdings of GKOS. Wellington Management Group LLP raised its position in shares of Glaukos by 294.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock worth $284,501,000 after purchasing an additional 1,630,270 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Glaukos by 47.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier’s stock worth $83,609,000 after purchasing an additional 207,338 shares during the last quarter. Loomis Sayles & Co. L P raised its position in shares of Glaukos by 21.6% in the 3rd quarter. Loomis Sayles & Co. L P now owns 673,751 shares of the medical instruments supplier’s stock worth $87,776,000 after purchasing an additional 119,527 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Glaukos in the 4th quarter worth about $16,910,000. Finally, State Street Corp raised its position in Glaukos by 5.3% in the 3rd quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier’s stock worth $254,626,000 after buying an additional 98,109 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insider Buying and Selling at Glaukos

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the sale, the insider now directly owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gilbert H. Kliman sold 10,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the sale, the director now directly owns 32,336 shares in the company, valued at approximately $4,859,454.08. This represents a 23.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,744 shares of company stock valued at $2,504,131 over the last ninety days. 6.40% of the stock is currently owned by company insiders.

Glaukos Trading Up 6.0 %

Glaukos stock opened at $102.43 on Monday. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12-month low of $85.04 and a 12-month high of $163.71. The firm has a market capitalization of $5.79 billion, a price-to-earnings ratio of -35.69 and a beta of 0.99. The firm has a 50 day moving average of $140.86 and a 200 day moving average of $137.69.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. As a group, research analysts predict that Glaukos Co. will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on GKOS. Piper Sandler reissued an “overweight” rating and issued a $180.00 target price (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Mizuho raised Glaukos from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $140.00 to $200.00 in a research report on Wednesday, February 19th. Wells Fargo & Company boosted their target price on Glaukos from $153.00 to $160.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Stephens raised Glaukos to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Morgan Stanley lowered Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 target price for the company. in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $163.25.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.